

Chronic Lymphocytic Leukemia

**A study to look at the safety and efficacy of obinutuzumab with bendamustine in people with a type of blood cancer called ‘chronic lymphocytic leukemia’ (GIBB)**

A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

**Trial Status**  
Completed

**Trial Runs In**  
1 Countries

**Trial Identifier**  
NCT02320487 ML29538

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

This is a Phase 2, open-label, multicenter study to evaluate the safety and efficacy of BG induction therapy in participants with previously untreated CLL. The anticipated time on study treatment is 24 weeks.

**Genentech, Inc.**  
Sponsor

**Phase 2**  
Phase

**NCT02320487 ML29538**  
Trial Identifiers

***Eligibility Criteria:***

**Gender**  
All

**Age**  
≥18 Years

**Healthy Volunteers**  
No